The merger nobody designs for

Picture the first all-company town hall after the deal closes. The deck has been built by two people, one from each side, and it shows. Slide four uses one company’s typeface and blue. Slide nine uses the other’s. Nobody set out to produce something incoherent, but that is what lands in front of three thousand employees on day one, and it tells them more about the state of the integration than any leadership message will.

The same thing happens across the website, the sales materials, the conference stand, and it compounds: two sets of visual habits, two versions of the company story, and every audience hearing a slightly different one.

“A logo derives its meaning from the quality of the thing it symbolizes, not the other way around.” Paul Rand wrote that in 1991, and every merger tests it. The mark is the one decision everyone can see, which makes it a useful way in. What a company does with it, and with everything sitting behind it, tells you whether the thinking happened. Three recent cases in science and health took three different routes.

When Bayer absorbed Monsanto in 2018, it left its own mark almost untouched. The Bayer cross was drawn in 1904 and and has barely changed since. It is the word BAYER set twice, once across and once down, sharing a single Y, inside a circle. That makes it a wordmark and a symbol at once, which is unusual; most marks in the sector are one or the other. The circle reads as a tablet, which is not incidental: the company stamped the cross onto its aspirin from 1910 to prevent counterfeiting, and the form still carries that. Against a mark holding that much history, and an acquired name carrying a good deal of baggage, there was little to decide. The cross stays, Monsanto goes.

But the decision did not stop at the corporate name. Roundup, DEKALB, Asgrow, Seminis and Deltapine all kept their own names and moved into the Bayer portfolio intact, because each carried equity with farmers that the parent name did not. One name retired, a dozen retained. That is brand architecture, not logo design, and it is the part that took the work.

Medtronic, acquiring Covidien in 2015, took the chance to redraw its own identity at the same time. Its emblem began as a painting the founder commissioned in the 1970s: a figure rising from lying flat to standing upright, and for decades that figure sat locked to the name. The 2015 redesign removed it; the primary mark became the wordmark alone, set in a lighter navy sans serif with slightly rounded forms. Dropping their most human asset from the logo at the exact moment they became a much bigger company would likely have taken nerve, but it holds up: the type carries the job across a portfolio far larger than before, and the figure, released from the logo to work on its own, has more presence for being used sparingly as part of the wider identity system.

The third case is not a merger but the aftermath of many. PerkinElmer had spent years acquiring life sciences businesses without ever fully folding them into one identity. In 2023 the company split, selling its applied, food and enterprise services businesses along with the PerkinElmer name, and the retained life sciences and diagnostics business needed a new identity with nothing established to work from. The company set the new Revvity wordmark in lowercase, with a single unbroken line running through the letters, and chose yellow over the blue commonly used in the sector. The futuristic, LED-like wordmark stands in stark contrast to much of the sector, and to the more traditional extended typeface of the old PerkinElmer logo.

The business was a stack of acquired companies, each with its own name and its own following. Someone went through them and decided, brand by brand, which names carried real equity with customers and stayed, BioLegend and EUROIMMUN among them, and which were folded in and renamed to match, so PerkinElmer Informatics became Revvity Signals and Genomics became Revvity Omics. The whole thing was sequenced over about a year, to the day the stock ticker changed. None of that is visible in the logo. All of it is why the logo worked.

Three different answers, each a judgement about what the mark needed to do. But the mark is only the part everyone can see. What separates an organisation that looks designed from one that looks assembled is the work underneath: the brand-by-brand decisions, the sequencing, and the rules that let two teams in two countries produce work that visibly comes from the same company.

The reason this work gets missed is mostly timing. Communication design gets commissioned after the deal closes, once something has to go out, which is precisely when it is too late to shape anything.

We have seen these questions get asked late far more often than early. Whose templates win, whose version of the story survives, who owns the decision at all. The answers are always harder than they would have been six months before.

Starting early means deciding, before the announcement, which house style wins where two collide, which sub-brands keep their names, what every document needs to say, and in what order the audiences hear it. Settled up front, these are a few weeks of work that everything else builds on.

But most organisations are not reading this before the deal. They are eighteen months in, surrounded by the inconsistent decks, and assuming the moment has passed. It hasn’t. The same decisions can be taken from the middle, and usually faster, because the evidence of what is not working is sitting in everyone’s inbox: an honest audit of what the organisation actually produces, a ruling on the collisions it turns up, and a master set of materials people can build from rather than around. The only thing that grows in the meantime is the pile of things to fix.